Granzyme B Antibody (2103A) [Unconjugated]

Western blot shows lysates of NK-92 human natural killer lymphoma cell line and NK-RL human natural killer lymphocytic leukemia cell line. PVDF membrane was probed with 0.5 µg/mL of Rabbit Anti-Human Granzyme B Monoclonal Antibody (Catalog # MAB29061) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Granzyme B at approximately 34 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Western blot shows lysates of NK‑92 human natural killer lymphoma cell line. PVDF membrane was probed with 0.1 µg/mL of Rabbit Anti-Human Granzyme B Monoclonal Antibody (Catalog # MAB29061) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (HAF008). A specific band was detected for Granzyme B at approximately 34 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1.

• Reactivity: Hu
• Applications: WB
• Clone: 2103A
• Clonality: Monoclonal
• Host: Rabbit
• Conjugate: Unconjugated

Granzyme B Antibody (2103A) [Unconjugated] Summary

• Additional Information: Recombinant Monoclonal Antibody.
• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Granzyme B
  Gly19-Tyr247
  Accession # P10144
• Specificity: Detects human Granzyme B in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Monoclonal
• Host: Rabbit
• Purity Statement: Protein A or G purified from cell culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot 0.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Granzyme B Antibody (2103A) [Unconjugated]

• C11
• CCPI
• CGL1
• CGL-1
• CSPB
• CSP-B
• CTLA1
• CTLA-1
• CTSGL1
• Fragmentin-2
• Granzyme B
• Granzyme-2
• GranzymeB
• GRB
• GrzB
• GZMB
• HLP
• SECT

Background

Granzyme B is a member of the granzyme family of the serine proteases found specifically in the cytotoxic granules of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells (1, 2). Granzyme B plays an essential role in granule-mediated apoptosis and may have additional roles in rheumatoid arthritis and in bacterial and viral infections (3). It activates various caspases and cleaves proteins such as aggrecan (3). Human Granzyme B is synthesized as a precursor (247 residues) with a signal peptide (residues 1-18), a pro peptide (residues 19-20), and a mature chain (residues 21-247) (4-6). The recombinant human (rh) Granzyme B consisting of residues 19-247 was expressed and purified. After being activated by active cathepsin C, rhGranzyme B cleaves a thioester substrate described previously (3).

1. Kam, C-M. et al. (2000) Biochim. Biophys. Acta 1477:307.
2. Smyth, M.J. et al. (1996) J. Leukoc. Biol. 60:555.
3. Froelich, C.J. (2004) in Handbook of Proteolytic Enzymes, Barrett, A.J. et al. eds. pp. 1549.
4. Schmid, J. and C. Weissman (1987) J. Immunol. 139:250.
5. Caputo, A. et al. (1988) J. Biol. Chem. 263:6363.
6. Trapani, J.A. et al. (1988) Proc. Natl. Acad. Sci. USA 85:6924.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Granzyme B Antibody (MAB29061)(1)

Publication using MAB29061

• Miriam Aarsund, Filip M. Segers, Yunjie Wu, Marit Inngjerdingen Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary NK cells or NK-cell lines stimulated with IL-15 or IL-12/15/18 Cancer Immunology, Immunotherapy 2022-09-01 [PMID: 35119498] (Western Blot, Human)

Bioinformatics

• Uniprot:
  • P10144()